TransCode Therapeutics RNAZ announced that it is floating a secondary issue of around 5.94 million shares of its common stock to the public at an issue price of $1.22 per share, ...

--TransCode Therapeutics, Inc., the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has received notice from the NASDAQ Stock ...

TransCode’s 2023 Phase 0 clinical trial produced evidence of delivery of a radiolabeled version of TTX-MC138 to metastatic lesions and pharmacodynamic activity, even at a microdose of the drug ...

España. India. Italia ...

TransCode Therapeutics, Inc. Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138 ...

--TransCode Therapeutics, Inc.,, an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its underwritten public offering of an ...

Shares of TransCode Therapeutics RNAZ have lost 99.62% year to date. This compares to the average annual return of -92.39%, meaning the stock has underperformed its historical averages.

TransCode expects that its cash of approximately $7.5 million as of September 30, 2023, is sufficient to fund planned operations into January 2024 but not for a full 12 months from the date of its ...

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA ...

Freeware application Transcode 360 runs on your Media Center computer and transcodes and streams movies encoded in the popular DivX and XviD formats to your Media Center extender so can still ...